Targovax is invited to present at upcoming investor conferences

Oslo, Norway, 21 January 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management team will present at upcoming investor conferences.

Date: 22 January 2019
Venue: Redeye Fight Cancer Seminar, Stockholm, Sweden
Presenter: Erik Digman Wiklund (CBO)

Presentation:
–    Time: 10:45 CET

Panel discussion:
–    The field of Immuno-oncology – how to optimize clinical development – what trends do you see in the market?
–    Time: 11:40 CET

The event can be followed live here.
The presentation will be available to download at www.targovax.com after the event.

Date: 7 February 2019
Venue: 5th annual Immuno-oncology (IO) 360°, NYC, USA
Presenter: Erik Digman Wiklund (CBO)

Panel discussion:
–    Fundraising in the Current IO Space
–    Time: 11:10 AM EST

————————————————————————————-

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert – FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com